Sub arachnoid block failure
RandomForest as a Variable Selection Tool for Biomarker Data Katja Remlinger GlaxoSmithKline, RTP, NA ICSA Applied Statistics Symposium June 6 th, 2007.
Clinical Review Process: An FDA Perspective Karen Midthun, M.D. Deputy Director of Medicine Center for Biologics Evaluation and Research FDA April 15,
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.
ILSI Health and Environmental Sciences Institute Updated April 2015 HESI Washington, DC USA HESI: Health and Environmental Sciences.
ILSI Health and Environmental Sciences Institute Syril D Pettit, MEM Executive Director February 25, 2015 Member Meeting HESI Washington, DC USA .
Application of Toxicology Databases in Drug Development (Estimating potential toxicity) Joseph F. Contrera, Ph.D. Director, Regulatory Research and Analysis.
DPC 083 ATAC Meeting Seattle February 24, 2002 Nancy Ruiz, MD.
DPC 083 ATAC Meeting Seattle February 24, 2002
1 Observations from the Antiviral Information Management System (AIMS) Database Jeffry Florian, Ph.D. CDER/OTS/OCP Division of Pharmacometrics, Reviewer.
1 Proton-Pump Inhibitor (PPI) Template for Pediatric Written Requests Pediatric Advisory Subcommittee of the Anti- Infective Drug Advisory Committee Hugo.
Receptor pharmacology or animal models for dose selection in humans? Bart Laurijssens Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, UK.